Free Trial

Opus Genetics 11/12/2024 Earnings Report

Opus Genetics logo
$0.89 -0.09 (-9.57%)
As of 04:00 PM Eastern

Opus Genetics EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.30
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Opus Genetics Revenue Results

Actual Revenue
$3.87 million
Expected Revenue
$1.17 million
Beat/Miss
Beat by +$2.70 million
YoY Revenue Growth
N/A

Opus Genetics Announcement Details

Quarter
Time
Before Market Opens

Conference Call Resources

Remove Ads

Opus Genetics Earnings Headlines

HC Wainwright Reaffirms "Buy" Rating for Opus Genetics (NASDAQ:IRD)
Trump’s Secret Weapon
Please don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.
HC Wainwright Forecasts Opus Genetics Q1 Earnings
Opus Genetics price target lowered to $8 from $9 at JonesResearch
See More Opus Genetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email.

About Opus Genetics

Opus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

View Opus Genetics Profile

More Earnings Resources from MarketBeat